Four healthy subjects and six patients with congestive heart failure (CHF) were given 3 mg oral and intravenous doses of bumetanide in a random crossover fashion. Bumetanide was analyzed by HPLC, and sodium and potassium was analyzed by flame photometry. Aside from a modest reduction in renal clearance, the kinetics of bumetanide in CHF were similar to those in healthy subjects. The extent of bioavailability was 81%, with a variability of 20% to 25% about the mean for both groups. The cumulative dynamic responses to bumetanide, whether administered orally or intravenously, were essentially the same in each group. Pharmacodynamic modeling showed that there were no significant differences between healthy subjects and patients with CHF in either ER. (bumetanide urinary excretion rate producing 50% of maximum drug effect) or S (slope), although the baseline effect was 15 times lower in CHF. The maximum effect attributable to bumetanide was twofold higher in healthy subjects and there was a significant correlation between this parameter and creatinine clearance (r = 0.964; p < 0.001). Overall, these results indicate that a predictable transition from 3 mg intravenous to oral doses of bumetanide is possible in CHF.
Bumetanide is a loop diuretic similar to furosemide with respect to its pharmacologic action and clinical indications. It differs from furosemide in that it is 40 times more potent on a milligram-per-milligram Bumetanide is highly protein bound' and relatively little drug undergoes glomerular filtration. However, bumetanide is actively secreted by the pars recta of the proximal tubule.' This is important because numerous investigators have shown that bumetanide exerts its primary natriuretic action on the thick ascending limb of Henle from the luminal side.' As a result, any pathophysiologic condition that affects the tubular secretion of bumetanide may attenuate the druginduced pharmacologic effect.
The pharmacokinetics of drugs may be affected by cardiac disease." Studies comparing healthy subjects with patients with congestive heart failure (CHF) have reported that changes in the bioavailability, volume of distribution, or clearance of drugs may occur in heart failure. Many investigators have focused on reduced drug clearance in CHF, which may be due to diminished blood flow to the kidney or liver or to compromised enzyme activity secondary to hepatic congestion. 1' However, very few studies have been completed that examine the effects of CHF on the bioavailability of compounds with low hepatic extraction, although alterations in absorption could result from changes in autonomic nervous activity, blood flow to the mesenteric area, or gut wall edema associated with cardiac congestion.
Both bumetanide and furosemide are used in the treatment of edema associated with CHF."' However, the pharmacodynamics of furosemide are variable, and suboptimal responses can occur, especially after oral dosing.'" These problems may be due, in part, to the incomplete and unpredictable bioavailability of furosemide.""-" In contrast, bumetanide has consistently high bioavailability in healthy subjects"°-"-" and in patients with hepatic or renal diseases.628 Nevertheless, pharmacokinetic and pharmacodynamic data for bumetanide in CHF are very limited.' Therefore, we undertook a study to determine the pharmacokinetics, pharmacodynamics, and bioavailability of bumetanide in patients with severe CHF after both oral and intravenous dosing. Parallel studies were carried out in healthy subjects for the purpose of comparison.
METHODS
Materials. Bumetanide tablets (1 mg; lot 0303-1) and intravenous solution (0.25 mg / ml; lot 3003) were obtained from Hoffmann-La Roche, Inc., Nutley, N.J. GUN PHARMACOL THER NOVEMBER 1988 All other chemicals and solvents were reagent grade or better, as previously reported.3°
Study participants. This study was performed in the Clinical Research Center and the University of Michigan Hospitals. The control group consisted of four healthy subjects as judged by medical history, physical examination, and standard laboratory test results, including a creatinine clearance (CLcR) determination (Table I) . The group of patients with CHF consisted of six individuals with class III or IV heart failure, according to the New York Heart Association criteria for functional capacity.' CL,R in these patients was stable at _ -35 ml/ min (Table I ). Patients must have been receiving a daily maintenance dose of 80 to 240 mg of furosemide as part of their prescribed drug therapy to be eligible for study. Patients were excluded from study if they had diabetes or signs and symptoms of hematologic, gastrointestinal, or hepatic diseases other than hepatic dysfunction associated with CHF. Patients receiving long-acting diuretics (i.e., metolazone, spironolactone) were also excluded from study. All diuretics were withheld for 24 hours before each study day, and drugs that have diuretic-like properties (i.e. , theophylline) or that may inhibit the diuretic responses (i.e., nonsteroidal antiinflammatory drugs) were not allowed for a minimum of 3 days before bumetanide administration (except for patient 6, who was taking one aspirin tablet per day). Each volunteer was instructed to avoid caffeine-containing beverages throughout the study. All participants were fully informed of the nature of the study and signed an informed consent form approved by the Committee to Review Grants for Clinical Research and Investigation Involving Human Beings of the University of Michigan Medical Center.
Study design. After an overnight fast, each patient received a 3 mg dose of bumetanide, either orally (three tablets) or intravenously, at 8 AM in a random crossover design. There was a minimum of at least 2 days between the two treatments. Bumetanide tablets were taken with 8 oz of water; the solution was infused at a constant rate over 3 minutes. For the intravenous dose, serial blood samples (3 ml) were drawn from the contralateral arm through an indwelling heparinized (10 U/ ml) scalp vein needle into tubes containing EDTA just before bumetanide dosing (blank) and at 3, 5, 10, 20, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 480 , and 1440 minutes after the start of the infusion. For the oral dose, serial blood samples were drawn just before dosing (blank) and at 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360, 420, 480 , and 1440 minutes after drug dos- ing. Blood samples were centrifuged immediately and the plasma was harvested and frozen. Voided urine was collected just before bumetanide administration (blank), every half hour for the first 3 hours, hourly for the next 5 hours, and then pooled from 8 to 24 hours after drug dosing. Plasma and urine samples were stored at 20° C until subsequent analysis.
Healthy subjects were kept relatively euvolemic throughout the study by replacing urinary losses isovolumetrically; 75% was replaced with intravenous administration of lactated Ringer's solution and the remaining 25% was replaced orally with water. Patients were allowed water and fruit juices throughout the study according to their prescribed fluid and dietary restrictions (i.e., a no-added-salt diet before and during study). A low-sodium lunch (30 to 50 mEq) was provided for each participant 4 hours after dosing. All plasma samples in healthy subjects and patients showed normal sodium concentrations.
Analytic procedures. Plasma and urine samples containing bumetanide were analyzed by a sensitive and specific HPLC assay.3° Plasma and urine samples were Bumetanide 489 assayed for sodium and potassium with a flame photometer (Model 455, Corning Medical and Scientific, Medfield, Mass.).
Protein binding. The plasma protein binding of bumetanide was determined for each participant by spiking the pooled plasma samples with bumetanide over a concentration range of 5 to 50 lig / ml. The concentration of bumetanide in the original samples was <2% of the spiked concentrations. Plasma (0.5 ml) was dialyzed against an equal volume of isotonic phosphate buffer (0.067 mol/ L at pH 7.4) at 37° C for 5 hours. Dialysis membranes with a molecular weight cutoff of 12,000 to 14,000 daltons and 1 ml dialysis cells were used throughout. Preliminary studies indicated that equilibrium was achieved within 2 hours and was maintained for 24 hours. Spiked plasma (0.2 ml) was prepared and analyzed as previously reported." Dialyzed buffer (0.2 ml) was mixed with 50 RI acetophenone (0.25 mg / ml) and injected into the HPLC Kinetics. Noninstantaneous mixing of drug in the sampling compartment was observed during the intravenous infusion of bumetanide. This resulted in peak plasma concentrations of bumetanide at times after the end of infusion. Therefore, plasma concentration-time curves of bumetanide after intravenous infusions were fit to the following general polyexponential equation:
k * i where C is the plasma concentration of bumetanide at time t, Ro is the rate of bumetanide infusion, V, is the volume of the central compartment, n is the number of exponents, Xi is the exponent of the ith exponential term, T is the infusion time, tlag, is the time lag between the beginning of the infusion and the appearance of bumetanide in the sampling compartment, and Ek is the sum of the exit rate constants from the kth compartment. Parameter estimates were obtained by the use of the nonlinear least-squares regression program MKMODEL." The number of exponents needed for each data set was determined by the application of Schwarz criterion,' ensuring that the coefficients of the CLIN PHARMACOL THER NOVEMBER 1988 corresponding bolus dose equation were all positive, and by visual examination of the residuals. Once the regression parameters were obtained, the coefficients (Ci) of the corresponding bolus dose equation could be calculated as follows":
where D is the total dose administered (Ro T).
The following pharmacokinetic parameters were then calculated from standard equations"'
In Eqs. 4 to 10, Vs, is the volume of distribution steady state; Vaa is that volume which, when multiplied by C in the log-linear phase, is equal to the amount of drug in the body; CL is the total plasma clearance; CL, is the renal clearance; CL, is the nonrenal clearance;
Ae(0 cc) is the amount of unchanged drug recovered in the urine at time infinity; ti is the biologic half-life;
X. is the smallest of the X, values; and F, is the fraction of the dose excreted unchanged in the urine. Plasma concentration-time profiles of oral bumetanide were not computer fit because of irregular absorption profiles in many of the participants. Pertinent kinetic parameters were therefore calculated by a noncompartmental approach. The biologic t112 with oral dosing (t112p.) was graphically determined by linear regression of In(C) vs. time with use of at least three data points from the log-linear terminal phase. CL, was determined by division of Ae(0 cc) by the plasma AUC(0 cc), calculated by a combination of the trapezoidal and log-trapezoidal rules and extrapolated to infinity as C1.1 ti,20/ 0.693. The peak plasma concentration (Cm.) and time to peak (tmax) after an oral dose were read directly from the plasma concentration-time curve.
Bioavailability. The extent of systemic availability
CL, = Ae(0-00)/ E C,/X;
of bumetanide was calculated by the area ratios of oral (po) and intravenous (iv) dosing:
by urinary excretion ratios:
and by correction for differences in CLR between oral and intravenous doses as suggested by Oie and Jung." 
where MRT equals the area under the first moment curve (AUMC; extrapolated to infinity) divided by AUC(0 -00). The AUMC was estimated by a combination of the trapezoidal and log-trapezoidal rules, extrapolated to infinity by tiast Clast t1/2/0.693 + CI.
(t11210.693)3. An MAT value that corrects for the time lag (tlagpo) before drug absorption was also calculated:
The flag,0 was estimated from absorption profiles by use of the exact Loo-Riegelman equation of Wagner' and the second derivative criterion of Proost" for evaluation of the two integrals of that equation. Dynamics. The relationship between the sodium excretion rate (E; in milliequivalents per minute) and the urinary excretion rate of bumetanide (ER; in micro- (16) where Eroax is the maximum effect attributable to the drug, ER50 is the urinary excretion rate of bumetanide that produces 50% of the Eroax, Eo is the baseline effect, and S is the parameter influencing the slope of the doseeffect curve. The unknown parameters (Erna., ER50, Eo, and S) were determined after intravenous dosing of bumetanide for each individual by use of the MKMODEL program.33 Phannacodynamic data were also reported as the 8-hour cumulative excretion of sodium and the overall efficiency (Eff ) of the response: (17) where AE and AAe are the amount of sodium and drug excreted in urine, respectively, over the same 8-hour period. AEo was estimated by multiplying the computerfitted value for baseline effect, E0, by 240 minutes.
Statistics. Unless otherwise indicated, data are expressed as the mean ± SD. Statistical differences between the healthy subjects and the patients with CHF were determined by one-way ANOVA. 
There was no statistically significant difference in fu between the two groups. Semilogarithmic plots of the plasma concentrationtime curves for intravenous and oral bumetanide are shown in Fig. 1 for healthy subjects and in Fig. 2 for patients with CHF. In all cases the intravenous infusion data were best fit by a biexponential equation (Table III).
Pharmacokinetic parameters calculated from intravenous bumetanide data are listed in Table IV and 5 minutes, and may have rendered any tlag,,, unobservable. It should be noted that although the number of subjects studied is small (n = 4), their kinetic parameters are remarkably similar to those reported by Lau et al.6 Kinetic data after oral bumetanide dosing are listed in Table V There was a highly significant difference in E,, between groups (1.23 .± 0.22 mEq/ min in patients with CHF vs. 2.65 ± 0.13 mEq/ min in healthy subjects; p < 0.001). Baseline sodium excretion was also 15 times greater in healthy subjects (0.016 -± 0.015 mEq / min in patients with CHF vs. 0.252 ± 0.078 mEq / min in healthy subjects; p < 0.001). There were no significant differences in ER50 or S. In fitting the data to the sigmoid Ema model, the first collection pe- Figs. 3 and 4) was omitted due to an observed counterclockwise hysteresis. This hysteresis, which has been reported for bumetanide in dogs7'47 and in man," results from a disequilibrium that occurs between the urine and effect compartments soon after dosing. Dynamic parameters were not evaluated during oral bumetanide dosing, because bumetanide excretion rates were not sufficient to describe all of the sigmoidal-shaped curve. Nevertheless, similar profiles were observed for the dose-response relationship of bumetanide when oral and intravenous data were superimposed on each other (Figs. 3 and 4 Bumetanide Excretion Rate (mcg/min) Fig. 3 . Mean ( ± SE) sodium excretion vs. urinary excretion rates of bumetanide in healthy subjects after 3 mg oral () and intravenous (0) doses. Solid line represents the computergenerated regression line based on the fitted regression parameters in Table VII (N) and intravenous (0) doses. Solid line represents the computergenerated regression line based on the fitted regression parameters in Table VII Creatinine Clearance (ml/min) cant increase in t112 between patients with CHF and normal subjects. This trend was also seen in our study (Tables IV and V) , but the differences were not statistically significant. Brater et al. suggested that this twofold increase in t172 observed for patients with CHF may be due to either a modest decrement in renal function or an increase in the volume of distribution, but they could not differentiate between the two because intravenous bumetanide was not administered in their study. In our study we saw no statistical difference in volumes of distribution. However, a substantial reduction (40%) in CI., did occur after oral bumetanide administration when comparing healthy subjects and patients with CHF
(1.83 ± 0.38 vs. 1.03 ± 0.46 ml/min/kg, respectively; p < 0.025). Additionally, a 20% reduction of renal clearance in patients with CHF (vs. healthy subjects) occurred when bumetanide was administered intravenously; this difference was not statistically significant.
As noted previously, there was a trend for the flag, in healthy subjects to be less than that in patients with CHF. Fig. 6 , a shift to the right is observed for the doseresponse curve in patients with CHF as compared with healthy subjects (right panel of figure) . A statistically significant difference in the corrected Erna), was found (1.57 x 10-± 8.19 x 10-3 for healthy subjects vs.
2.10 x 10' ± 7.78 x 10-3 for patients with CHF; p < 0.01), but this difference was only 25% and may reflect the limited number of individuals studied. The corrected baseline response was statistically different between groups (1.49 x 10-2 ± 2.19 x 10-3 for healthy subjects vs. 3.10 x 10-3 ± 1.24 x 10 -3 for patients with CHF; p < 0.001) and, as explained previously, may be the result of differences in dietary intake of sodium and in replacement of urinary fluid losses between groups. Additionally, there was a two-to threefold increase in the corrected value for ER50 (2.94 x 10-2 3.73 x 10-3 lig/ ml for healthy subjects vs. 7.67 x 10-2 ± 1.24 x 10-3 p,g/ ml for patients with CHF; p < 0.05). These results may indicate that acute diuretic tolerance is occurring in CHF as urinary losses were not replaced, or that there may be diuretic resistance in CHF. If there is an enhancement of proximal tubular sodium reabsorption in CHF,'" it would take higher urinary concentrations of bumetanide to elicit the same response in a patient with CHF as compared with a healthy subject.
When the dose-response parameters of healthy subjects in our study were compared with healthy subjects in a study by Lau et al. , 6 there were no significant differences found between E.,R, (2.65 0.24 vs. 3.82 ± 1.13 mEq/ min, respectively) and the slope factor, S (2.01 ± 0.56 vs. 1.61 ± 0.24, respectively).
However, there were significant differences in both ER50 (3.46 ± 0.93 vs. 14.0 ± 7.8 lig /min, respectively; p < 0.05) and E. (0.252 ± 0.078 vs. 0.085 -± 0.065 mEq/ min, respectively; p < 0.001). Previous studies in animals"'" and man56 have shown that an acute tolerance can develop to furosemide when fluid and electrolyte replacement is inadequate. More recently, similar results have been confirmed for bumetanide in dogs' in which a statistically significant increase of ER50 occurred with increasing sodium and fluid deficits due to uncompensated urinary losses. These studies have demonstrated that when there is inadequate replacement of urinary losses, body mechanisms are rapidly brought into play within a single dose of diuretic to conserve body fluids. In the study by Lau et al., subjects were kept euvolemic by isovolumetric replacement of urinary losses, but this was done orally with fruit juices. In our study, urinary losses were replaced intravenously with lactated Ringer's solution. It may be that oral absorption of fluids cannot occur at a rate rapid enough to compensate for urinary losses. Consequently, acute tolerance to bumetanide was evident in the study by Lau et al. but not in the present one in healthy subjects.
Ideally, strict and consistent dietary control between the treatment groups is preferable. However, because we were ethically unable to replace intravenous fluids for urine losses in patients with CHF, and because patients' diets were adjusted as tolerated by the degree of heart failure, it was decided to study each participant while he or she was eating his or her normal, stabilized diet. Nonetheless, given this clinical necessity, the variability in dynamic parameters (Erna,, ER, S) in healthy subjects and in patients with CHF was comparable (coefficient of variation, 10% to 40%) with those studies in which diet was strictly controlled." Baseline values (E.) tend to vary considerably between studies and may reflect the hydration status of the individual as well as the method of data analysis.
In conclusion, our results suggest that aside from a modest reduction in CLR, the pharmacokinetics of bumetanide in patients with CHF are similar to those in healthy subjects. The extent of bioavailability of 3 mg oral doses of bumetanide is approximately 80%, with a variability about the mean of 20% to 25% in both patients with CHF and healthy volunteers. The cumulative pharmacodynamic responses to bumetanide, whether administered orally or intravenously, were not significantly different. As a result, it appears that with bumetanide the clinician can make a predictable transition from an intravenous 3 mg dose to a 3 mg oral maintenance dose in patients with CHF. Because the two modes of administration provide nearly identical respones, the intravenous route should be reserved for those patients who require a rapid onset of action or in whom oral therapy is not appropriate.
